[Immunoglobulin-G4-related disease].
Immunglobulin-G4-assoziierte Erkrankung.
Fibrosis
Granulomatous disease
Plasma cells
Tumor
T‑cells
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
05
05
2022
pubmed:
30
6
2022
medline:
15
9
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
After years of confusion about apparently distinct clinical disease symptoms, the term IgG4-related disease (IgG4-RD) has been coined in 2001, uniting these fibroinflammatory clinical entities with a tendency for tumorous enlargement and tissue fibrosis. Over the past two decades, experimental and clinical studies could make astounding progress in the understanding of this elusive disease. By now, we have a reasonable idea of the pathophysiological mechanisms, which opens up new avenues for therapeutic approaches. It seems like a dense lymphoplasmacytic cell infiltrate, consisting of B‑cells, IgG4 Nachdem die Ig(Immunglobulin)G4-assoziierte Erkrankung („IgG4-related disease“ [IgG4-RD]) im Jahr 2001 erstmals vermeintlich voneinander unabhängige klinische Krankheitssymptome zu einer eigenständigen Krankheitsentität mit potenzieller Multiorganbeteiligung zusammenfasste, konnten experimentelle und klinische Studien erstaunliche Fortschritte beim Verständnis der entzündlich fibrosierenden Erkrankung erzielen. Pathophysiologisch scheint ein Zusammenspiel aus B‑Zellen, IgG4
Autres résumés
Type: Publisher
(ger)
Nachdem die Ig(Immunglobulin)G4-assoziierte Erkrankung („IgG4-related disease“ [IgG4-RD]) im Jahr 2001 erstmals vermeintlich voneinander unabhängige klinische Krankheitssymptome zu einer eigenständigen Krankheitsentität mit potenzieller Multiorganbeteiligung zusammenfasste, konnten experimentelle und klinische Studien erstaunliche Fortschritte beim Verständnis der entzündlich fibrosierenden Erkrankung erzielen. Pathophysiologisch scheint ein Zusammenspiel aus B‑Zellen, IgG4
Identifiants
pubmed: 35767095
doi: 10.1007/s00393-022-01229-x
pii: 10.1007/s00393-022-01229-x
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Immunoglobulin G
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
549-557Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Aalberse RC, Stapel SO, Schuurman J et al (2009) Immunoglobulin G4: an odd antibody. Clin Exp Allergy 39:469–477
pubmed: 19222496
doi: 10.1111/j.1365-2222.2009.03207.x
Akiyama M, Kaneko Y, Hayashi Y et al (2016) IgG4-related disease involving vital organs diagnosed with lip biopsy: a case report and literature review. Medicine 95:e3970
pubmed: 27311008
pmcid: 4998494
doi: 10.1097/MD.0000000000003970
Akiyama M, Suzuki K, Yamaoka K et al (2015) Number of circulating follicular helper 2 T cells correlates with IgG4 and Interleukin‑4 levels and plasmablast numbers in IgG4-related disease. Arthritis Rheumatol 67:2476–2481
pubmed: 25989153
doi: 10.1002/art.39209
Behzadi F, Suh CH, Jo VY et al (2021) Imaging of IgG4-related disease in the head and neck: a systematic review, case series, and pathophysiology update. J Neuroradiol 48:369–378
pubmed: 33516733
doi: 10.1016/j.neurad.2021.01.006
Brito-Zeron P, Kostov B, Bosch X et al (2016) Therapeutic approach to IgG4-related disease: a systematic review. Medicine 95:e4002
pubmed: 27368010
pmcid: 4937924
doi: 10.1097/MD.0000000000004002
Campochiaro C, Ramirez GA, Bozzolo EP et al (2016) IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 45:135–145
pubmed: 26398142
doi: 10.3109/03009742.2015.1055796
Carruthers MN, Stone JH, Deshpande V et al (2012) Development of an IgG4-RD responder index. Int J Rheumatol 2012:259408
pubmed: 22611406
pmcid: 3348627
doi: 10.1155/2012/259408
Carruthers MN, Topazian MD, Khosroshahi A et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74:1171–1177
pubmed: 25667206
doi: 10.1136/annrheumdis-2014-206605
Chen Y, Lin W, Yang H et al (2018) Aberrant expansion and function of follicular helper T cell subsets in IgG4-related disease. Arthritis Rheumatol 70:1853–1865
pubmed: 29781221
pmcid: 6220938
doi: 10.1002/art.40556
Danlos FX, Rossi GM, Blockmans D et al (2017) Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome. Autoimmun Rev 16:1036–1043
pubmed: 28780079
doi: 10.1016/j.autrev.2017.07.020
Della-Torre E, Bozzalla-Cassione E, Sciorati C et al (2018) A CD8alpha-subset of CD4+SLAMF7+ Cytotoxic T cells is expanded in patients with IgG4-related disease and decreases following glucocorticoid treatment. Arthritis Rheumatol 70:1133–1143
pubmed: 29499100
pmcid: 6019645
doi: 10.1002/art.40469
Della-Torre E, Rigamonti E, Perugino C et al (2020) B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol 145:968–981.e14
pubmed: 31319101
doi: 10.1016/j.jaci.2019.07.004
Deshpande V, Zen Y, Chan JK et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181–1192
pubmed: 22596100
doi: 10.1038/modpathol.2012.72
Ebbo M, Grados A, Bernit E et al (2012) Pathologies associated with serum IgG4 elevation. Int J Rheumatol 2012:602809
pubmed: 22966232
pmcid: 3433130
doi: 10.1155/2012/602809
Furukawa S, Moriyama M, Miyake K et al (2017) Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep 7:42413
pubmed: 28205524
pmcid: 5304322
doi: 10.1038/srep42413
Furukawa S, Moriyama M, Tanaka A et al (2015) Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol 156:9–18
pubmed: 25450336
doi: 10.1016/j.clim.2014.10.008
Hamano H, Kawa S, Horiuchi A et al (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344:732–738
pubmed: 11236777
doi: 10.1056/NEJM200103083441005
Hubers LM, Vos H, Schuurman AR et al (2018) Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut 67:728–735
pubmed: 28765476
Iaccarino L, Talarico R, Bozzalla-Cassione E et al (2022) Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners. Clin Exp Rheumatol. https://doi.org/10.55563/clinexprheumatol/qq9qup
doi: 10.55563/clinexprheumatol/qq9qup
pubmed: 35930472
Ito F, Kamekura R, Yamamoto M et al (2019) IL-10(+) T follicular regulatory cells are associated with the pathogenesis of IgG4-related disease. Immunol Lett 207:56–63
pubmed: 30658078
doi: 10.1016/j.imlet.2019.01.008
Karadeniz H, Vaglio A (2020) IgG4-related disease: a contemporary review. Turk J Med Sci 50:1616–1631
pubmed: 32777900
pmcid: 7672352
doi: 10.3906/sag-2006-375
Karim F, Loeffen J, Bramer W et al (2016) IgG4-related disease: a systematic review of this unrecognized disease in pediatrics. Pediatr Rheumatol Online J 14:18
pubmed: 27012661
pmcid: 4807566
doi: 10.1186/s12969-016-0079-3
Kawakami T, Mizushima I, Yamada K et al (2019) Abundant a proliferation-inducing ligand (APRIL)-producing macrophages contribute to plasma cell accumulation in immunoglobulin G4-related disease. Nephrol Dial Transplant 34:960–969
pubmed: 30325430
doi: 10.1093/ndt/gfy296
Khosroshahi A, Wallace ZS, Crowe JL et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67:1688–1699
pubmed: 25809420
doi: 10.1002/art.39132
Kubo S, Kanda R, Nawata A et al (2022) Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. Rmd Open. https://doi.org/10.1136/rmdopen-2021-002086
doi: 10.1136/rmdopen-2021-002086
pubmed: 35260476
pmcid: 8906049
Lanzillotta M, Della-Torre E, Stone JH (2017) Roles of plasmablasts and B cells in IgG4-related disease: implications for therapy and early treatment outcomes. Curr Top Microbiol Immunol 401:85–92
pubmed: 28091934
Maehara T, Mattoo H, Mahajan VS et al (2018) The expansion in lymphoid organs of IL-4(+) BATF(+) T follicular helper cells is linked to IgG4 class switching in vivo. Life Sci Alliance. https://doi.org/10.26508/lsa.201800050
doi: 10.26508/lsa.201800050
pubmed: 29984361
pmcid: 6034714
Maillette De Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL et al (2013) Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 57:2390–2398
pubmed: 23300096
doi: 10.1002/hep.26232
Manger B, Schett G (2021) Jan Mikulicz-Radecki (1850–1905): return of the surgeon. Ann Rheum Dis 80:8–10
pubmed: 32988841
doi: 10.1136/annrheumdis-2020-218843
Martín-Nares E, Hernandez-Molina G (2021) What is the meaning of ANCA positivity in IgG4-related disease? Rheumatology 60:3845–3850
pubmed: 33547775
doi: 10.1093/rheumatology/keab124
Maslinska M, Dmowska-Chalaba J, Jakubaszek M (2022) The role of IgG4 in autoimmunity and rheumatic diseases. Front Immunol. https://doi.org/10.3389/fimmu.2021.787422
doi: 10.3389/fimmu.2021.787422
pubmed: 35145508
pmcid: 8821096
Mattoo H, Mahajan VS, Della-Torre E et al (2014) De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 134:679–687
pubmed: 24815737
pmcid: 4149918
doi: 10.1016/j.jaci.2014.03.034
Mattoo H, Mahajan VS, Maehara T et al (2016) Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138:825–838
pubmed: 26971690
pmcid: 5014627
doi: 10.1016/j.jaci.2015.12.1330
Mattoo H, Stone JH, Pillai S (2017) Clonally expanded cytotoxic CD4(+) T cells and the pathogenesis of IgG4-related disease. Autoimmunity 50:19–24
pubmed: 28166682
pmcid: 5880292
doi: 10.1080/08916934.2017.1280029
Perugino CA, Alsalem SB, Mattoo H et al (2019) Identification of galectin‑3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol 143:736–745.e6
pubmed: 29852256
doi: 10.1016/j.jaci.2018.05.011
Perugino CA, Stone JH (2020) IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol 16:702–714
pubmed: 32939060
doi: 10.1038/s41584-020-0500-7
Sasaki T, Akiyama M, Kaneko Y et al (2018) Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. Clin Exp Rheumatol 36(Suppl 112):186–189
pubmed: 29846165
Schmidkonz C, Rauber S, Atzinger A et al (2020) Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis 79:1485–1491
pubmed: 32719042
doi: 10.1136/annrheumdis-2020-217408
Shiokawa M, Kodama Y, Sekiguchi K et al (2018) Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaq0997
doi: 10.1126/scitranslmed.aaq0997
pubmed: 30089633
Strehl JD, Hartmann A, Agaimy A (2011) Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 64:237–243
pubmed: 21233087
doi: 10.1136/jcp.2010.085613
Tang CSW, Sivarasan N, Griffin N (2018) Abdominal manifestations of IgG4-related disease: a pictorial review. Insights Imaging 9:437–448
pubmed: 29696607
pmcid: 6108972
doi: 10.1007/s13244-018-0618-1
Uchida K, Masamune A, Shimosegawa T et al (2012) Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012:358371
pubmed: 22899936
pmcid: 3415093
Wallace ZS, Deshpande V, Mattoo H et al (2015) IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67:2466–2475
pubmed: 25988916
pmcid: 4621270
doi: 10.1002/art.39205
Wallace ZS, Khosroshahi A, Carruthers MD et al (2018) An international multispecialty validation study of the IgG4-related disease responder index. Arthritis Care Res 70:1671–1678
doi: 10.1002/acr.23543
Wallace ZS, Mattoo H, Carruthers M et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74:190–195
pubmed: 24817416
doi: 10.1136/annrheumdis-2014-205233
Wallace ZS, Mattoo H, Mahajan VS et al (2016) Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology 55:1000–1008
pubmed: 26888853
pmcid: 4900135
doi: 10.1093/rheumatology/kev438
Wallace ZS, Naden RP, Chari S et al (2020) The 2019 American college of rheumatology/European league against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 72:7–19
pubmed: 31793250
doi: 10.1002/art.41120
Wallace ZS, Zhang Y, Perugino CA et al (2019) Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 78:406–412
pubmed: 30612117
doi: 10.1136/annrheumdis-2018-214603
Wang L, Zhang P, Zhang X et al (2019) Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients. Rheumatology 58:820–830
pubmed: 30561747
doi: 10.1093/rheumatology/key397
Yu T, Wu Y, Liu J et al (2022) The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis. Arthritis Res Ther 24:14
pubmed: 34986892
pmcid: 8728936
doi: 10.1186/s13075-021-02652-2